These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 30701884)

  • 41. The Two Faces of Interleukin-17A in Atherosclerosis.
    Akhavanpoor M; Akhavanpoor H; Gleissner CA; Wangler S; Doesch AO; Katus HA; Erbel C
    Curr Drug Targets; 2017; 18(7):863-873. PubMed ID: 28034277
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Future of IL-1 Targeting in Kidney Disease.
    Afsar B; Covic A; Ortiz A; Afsar RE; Kanbay M
    Drugs; 2018 Jul; 78(11):1073-1083. PubMed ID: 29968152
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Emerging Role of Inflammation in Cardiovascular Disease.
    Martinez BK; White CM
    Ann Pharmacother; 2018 Aug; 52(8):801-809. PubMed ID: 29557210
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complement activation by cholesterol crystals triggers a subsequent cytokine response.
    Niyonzima N; Halvorsen B; Sporsheim B; Garred P; Aukrust P; Mollnes TE; Espevik T
    Mol Immunol; 2017 Apr; 84():43-50. PubMed ID: 27692470
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of Interleukin-1β Inhibition on Incident Anemia: Exploratory Analyses From a Randomized Trial.
    Vallurupalli M; MacFadyen JG; Glynn RJ; Thuren T; Libby P; Berliner N; Ridker PM
    Ann Intern Med; 2020 Apr; 172(8):523-532. PubMed ID: 32203978
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting the residual cardiovascular risk by specific anti-inflammatory interventions as a therapeutic strategy in atherosclerosis.
    Hafiane A; Daskalopoulou SS
    Pharmacol Res; 2022 Apr; 178():106157. PubMed ID: 35257900
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond.
    Libby P
    J Am Coll Cardiol; 2017 Oct; 70(18):2278-2289. PubMed ID: 29073957
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inflammation as a Therapeutic Target in Atherosclerosis.
    Nguyen MT; Fernando S; Schwarz N; Tan JT; Bursill CA; Psaltis PJ
    J Clin Med; 2019 Jul; 8(8):. PubMed ID: 31357404
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Inflammation and atherosclerosis – last piece of the puzzle has fallen into place].
    Jonasson L; Hansson G
    Lakartidningen; 2017 Oct; 114():. PubMed ID: 29292899
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inflammasomes as Potential Therapeutic Targets in Atherosclerotic Cardiovascular Disease.
    Wang P; Ma J; Zhang R
    Endocr Metab Immune Disord Drug Targets; 2022; 22(14):1378-1389. PubMed ID: 35392792
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cholesterol crystals enhance TLR2- and TLR4-mediated pro-inflammatory cytokine responses of monocytes to the proatherogenic oral bacterium Porphyromonas gingivalis.
    Køllgaard T; Enevold C; Bendtzen K; Hansen PR; Givskov M; Holmstrup P; Nielsen CH
    PLoS One; 2017; 12(2):e0172773. PubMed ID: 28235036
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-cytokine therapy for prevention of atherosclerosis.
    Kirichenko TV; Sobenin IA; Nikolic D; Rizzo M; Orekhov AN
    Phytomedicine; 2016 Oct; 23(11):1198-210. PubMed ID: 26781385
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oxidized low-density lipoprotein induces secretion of interleukin-1β by macrophages via reactive oxygen species-dependent NLRP3 inflammasome activation.
    Jiang Y; Wang M; Huang K; Zhang Z; Shao N; Zhang Y; Wang W; Wang S
    Biochem Biophys Res Commun; 2012 Aug; 425(2):121-6. PubMed ID: 22796220
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease.
    Aday AW; Ridker PM
    Front Cardiovasc Med; 2019; 6():16. PubMed ID: 30873416
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders.
    Church LD; McDermott MF
    Curr Opin Mol Ther; 2009 Feb; 11(1):81-9. PubMed ID: 19169963
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inflammation and atherosclerosis: Cardiovascular evaluation in patients with autoimmune diseases.
    Escárcega RO; Lipinski MJ; García-Carrasco M; Mendoza-Pinto C; Galvez-Romero JL; Cervera R
    Autoimmun Rev; 2018 Jul; 17(7):703-708. PubMed ID: 29730525
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis.
    Freigang S; Ampenberger F; Spohn G; Heer S; Shamshiev AT; Kisielow J; Hersberger M; Yamamoto M; Bachmann MF; Kopf M
    Eur J Immunol; 2011 Jul; 41(7):2040-51. PubMed ID: 21484785
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hydrogen-Rich Saline Attenuated Subarachnoid Hemorrhage-Induced Early Brain Injury in Rats by Suppressing Inflammatory Response: Possible Involvement of NF-κB Pathway and NLRP3 Inflammasome.
    Shao A; Wu H; Hong Y; Tu S; Sun X; Wu Q; Zhao Q; Zhang J; Sheng J
    Mol Neurobiol; 2016 Jul; 53(5):3462-3476. PubMed ID: 26091790
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases.
    Arida A; Protogerou AD; Kitas GD; Sfikakis PP
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29954107
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches.
    Tsioufis P; Theofilis P; Tsioufis K; Tousoulis D
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.